Evidence map›Paper›PMID 38444264›Full record

ArticleNanotoxicology2024

Investigation of sex-based differences in the immunotoxicity of silver nanoparticles.

Brandon Canup, Paul Rogers, Angel Paredes, Wimolnut Manheng, Beverly Lyn-Cook, Tariq Fahmi

Open access · greenAbstract read
In one paragraph

Article in Nanotoxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Brandon CanupDivision of Biochemical Toxicology, Office of Research, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Paul RogersDivision of Bioinformatics and Biostatistics, Office of Research, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Angel ParedesNanotechnology Core Facility, Office of Scientific Coordination, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Wimolnut ManhengDivision of Hematology Oncology Toxicology, Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Beverly Lyn-CookDivision of Biochemical Toxicology, Office of Research, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
Tariq FahmiDivision of Biochemical Toxicology, Office of Research, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
United States Food and Drug Administration · USNational Center for Toxicological Research · USCenter for Drug Evaluation and Research · US

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

The growing application of silver nanoparticles (AgNPs) in consumer, healthcare, and industrial products has raised concern over potential health implications due to increasing exposure. The evaluation of the immune response to nanomaterials is one of the key criteria to assess their biocompatibility. There are well-recognized sex-based differences in innate and adaptive immune responses. However, there is limited information available using human models. The aim was to investigate the potential sex-based differences in immune functions after exposure to AgNPs using human peripheral blood mononuclear cells (PBMCs) and plasma from healthy donors. These functions include inflammasome activation, cytokine expression, leukocyte proliferation, chemotaxis, plasma coagulation, and complement activation. AgNPs were characterized by dynamic light scattering and transmission electron microscopy. Inflammasome activation by AgNPs was measured after 6- and 24-hours incubations. AgNPs-induced inflammasome activation was significantly higher in the females, especially for the 6-hour exposure. No sex-based differences were observed for Ag ions controls. Younger donors exhibited significantly more inflammasome activation than older donors after 24-hours exposure. IL-10 was significantly suppressed in males and females after exposure. AgNPs suppressed leukocyte proliferation similarly in males and females. No chemoattractant effects, no alterations in plasma coagulation, or activation of the complement were observed after AgNPs exposure. In conclusion, the results highlight that there are distinct sex-based differences in inflammasome activation after exposure to AgNPs in human PBMCs. The results highlight the importance of considering sex-based differences in inflammasome activation induced by exposure to AgNPs in any future biocompatibility assessment for products containing AgNPs.

Indexed as

Leukocytes, MononuclearMetal NanoparticlesSilverAdultCell ProliferationCytokinesFemaleHumansInflammasomesMaleMiddle AgedSex FactorsYoung AdultCytokinesInflammasomesSilverimmunotoxicityInflammasomeperipheral blood mononuclear cellssex-based differencesilver nanoparticles

Identifiers

PMID38444264
PMCPMC12445140
OpenAlexW4392516626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.